Supplemental Financials 1Q24 Earnings () ORTHOFIX® Forward Looking Statements ©2024 Orthofix Medical Inc. All rights reserved | 1 May 7, 2024 ©2024 Orthofix Medical Inc. All rights reserved | Q1 Adjusted Gross Margin: 70.3% vs 70.7% in 1Q23 Q1 R&D: $19.5M; 10.3% of sales vs $23.3M in 1Q23; 13.3% of sales This presentation contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, relatin ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 0-19961 ORTHOFIX MEDICAL INC. (Exact name of registrant as specified in its charter) Delaware 98-1340767 (State or other jurisdicti ...

Exhibit 99.1 Orthofix Reports First Quarter 2024 Results Recent Highlights • Net sales of $188.6 million, an increase of 7.7% on a reported basis and 7.5% on a constant currency basis over prior year • Bone Growth Therapies net sales growth of 10%, marking five consecutive quarters with double-digit net sales increases • U.S. Spine Fixation1 net sales growth of 16%, driven by distribution expansion and further penetration in existing accounts • Global Orthopedics net sales growth of 5% on a reported basis, ...

Company Participants Conference Call Participants Good afternoon, and welcome to Orthofix MedicalÂ's Q4 and Full Year 2023 Earnings Call. All participants are in a listen-only mode. After the speakers' remarks, we will have a question-and-answer session. [Operator Instructions] As a reminder, this conference call is being recorded. Good afternoon, everyone. Welcome to the Orthofix fourth quarter 2023 earnings call. Joining me on the call today are President and Chief Executive; Massimo Calafiore, and Chief ...

Click to edit Master title style 5 NewCo $ (22.049) $ (27.274) $ 13.969 3.141 1.705 0.390 6.286 1.781 8.842 1,953 ' 1.007 2.630 0.426 $ 41.694 $ 37.291 $ 19.645 $ 10.017 Adjusted Gross Margin ($ in millions) NewCo Change 122.229 $ 200.415 $ 186.373 6 8.939 0.102 0.144 · 0.125 7.037 0.373 (0.072) Adjusted gross profit 16.320 68.9% 0.431 11.689 3.481 A reconciliation of proforma Adjusted EBITDA for each quarter of 2022 to the nearest GAAP financial measure for each of SeaSpine and Orthofix is presented on thi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 0-19961 ORTHOFIX MEDICAL INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) ...

Exhibit 99.1 Orthofix Reports Fourth Quarter and Full Year 2023 Results Recent Highlights LEWISVILLE, Texas — March 5, 2024 — Orthofix Medical Inc. (NASDAQ:OFIX) today reported its financial results for the fourth quarter and year ended December 31, 2023, and issued guidance for the full year 2024. Fourth quarter net sales were $200.4 million, an increase of 64% on a reported basis and 7% on a pro forma constant currency basis. Net loss was $(22.2) million and earnings per share ("EPS") was $(0.59) on a rep ...

Orthofix Medical Inc. (NASDAQ:OFIX) Q3 2023 Earnings Call Transcript November 8, 2023 4:30 PM ET Company Participants Conference Call Participants Operator I would now like to turn the call over to Louisa Smith from the Gilmartin Group for a few introductory comments. [Technical Difficulty] and good afternoon, everyone. Welcome to the Orthofix third quarter 2023 earnings call. Joining me on the call today are Board of Directors Chair and Interim Chief Executive Officer, Cathy Burzik, and Interim Chief Finan ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 0-19961 ORTHOFIX MEDICAL INC. (Exact name of registrant as specified in its charter) Delaware 98-1340767 (State or other jurisd ...

We expect adjusted gross margins to increase over time as we recognize efficiencies from spinal implant set utilization and product rationalization as well as other economies of scale that we expect to generate from the merger. GAAP gross margin in the second half of 2023 is likely to be negatively impacted by additional mergerrelated E&O inventory charges driven by further product rationalization decisions. We plan to host an Investor Day at our Louisville, Texas headquarters on Wednesday, September 20, at ...